• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review

by | Mar 27, 2025 | Publications

Front Oncol. 2025 Mar 12;15:1550644. doi: 10.3389/fonc.2025.1550644. eCollection 2025. ABSTRACT INTRODUCTION: Anti-CD38-based therapy has become a backbone regimen for the treatment of multiple myeloma (MM), approved in first-, second-, and third-line settings. The...

A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab

by | Mar 25, 2025 | Publications

Explor Target Antitumor Ther. 2025 Mar 19;6:1002300. doi: 10.37349/etat.2025.1002300. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow,...

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

by | Mar 14, 2025 | Publications

Blood Cancer J. 2025 Mar 13;15(1):37. doi: 10.1038/s41408-025-01253-5. ABSTRACT The treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (TE-NDMM) has evolved with the introduction of daratumumab-based quadruplet regimens. Adding...

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review

by | Mar 8, 2025 | Publications

Cancer Med. 2025 Mar;14(5):e70585. doi: 10.1002/cam4.70585. ABSTRACT BACKGROUND: There is a lack of clear guidance on the appropriate next choice of therapy for patients with relapsed/refractory multiple myeloma who become refractory to daratumumab, an anti-CD38...

Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis

by | Feb 18, 2025 | Publications

Ther Adv Hematol. 2025 Feb 17;16:20406207251319593. doi: 10.1177/20406207251319593. eCollection 2025. ABSTRACT BACKGROUND: Renal impairment is one of the common characteristics of multiple myeloma (MM) and makes management of MM more complicated. Even though...

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis

by | Feb 7, 2025 | Publications

Hematology. 2025 Dec;30(1):2462249. doi: 10.1080/16078454.2025.2462249. Epub 2025 Feb 6. ABSTRACT BACKGROUND: The current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between...
« Older Entries
Next Entries »

Recent Content

  • Utilizing AI in Prostate Cancer Care and Management
  • KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
  • Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
  • Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
  • Op-Ed: Expand Patient Choice to Lower Medication Costs
  • Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
  • Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
  • Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
  • SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
  • GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT